[Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Rakov
A L
AL
Makarov
Iu S
IuS
Gorbakov
V V
VV
Mironenko
D A
DA
Golochalova
T V
TV
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D015738:Famotidine / Q000627:therapeutic use*; D005750:Gastric Juice / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009853:Omeprazole / Q000627:therapeutic use*; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D064750:Rabeprazole; D015738:Famotidine; D009853:Omeprazole